69183-200 NDC - EYES ALIVE (CARBOXYMETHYLCELLULOSE SODIUM)

Drug Information

Product NDC: 69183-200

Proprietary Name: Eyes Alive

Non Proprietary Name: CARBOXYMETHYLCELLULOSE SODIUM

Active Ingredient(s):
  • 5 mg/mL CARBOXYMETHYLCELLULOSE SODIUM, UNSPECIFIED FORM


Administration Route(s): INTRAOCULAR

Dosage Form(s): LIQUID

Labeler Information

Labeler Name: DIVISION 5 LABS, INC.
Product Type: HUMAN OTC DRUG
FDA Application Number: part349
Marketing Category: OTC MONOGRAPH FINAL
Start Marketing Date:2/1/2015

Package Information

No. Package Code Package Description Billing Unit
169183-200-00100 AMPULE in 1 CARTON (69183-200-00) > .6 mL in 1 AMPULE
269183-200-022 AMPULE in 1 POUCH (69183-200-02) > .6 mL in 1 AMPULE
369183-200-044 AMPULE in 1 POUCH (69183-200-04) > .6 mL in 1 AMPULE
469183-200-088 AMPULE in 1 CARTON (69183-200-08) > .6 mL in 1 AMPULE
569183-200-3232 AMPULE in 1 CARTON (69183-200-32) > .6 mL in 1 AMPULE
669183-200-5252 AMPULE in 1 CARTON (69183-200-52) > .6 mL in 1 AMPULE
769183-200-7272 AMPULE in 1 CARTON (69183-200-72) > .6 mL in 1 AMPULE

NDC Record

Field Name Field Value Definition
PRODUCT NDC69183-200The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
PRODUCT TYPE NAMEHUMAN OTC DRUGIndicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
PROPRIETARY NAMEEyes AliveThe proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.
PROPRIETARY NAME SUFFIXLubricatingA suffix to the proprietary name, a value here should be appended to the ProprietaryName field to obtain the complete name of the product. This suffix is often used to distinguish characteristics of a product such as extended release (“XR”) or sleep aid (“PM”). Although many companies follow certain naming conventions for suffices, there is no recognized standard.
NON PROPRIETARY NAMECARBOXYMETHYLCELLULOSE SODIUMThe non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
DOSAGE FORM NAMELIQUIDThe translation of the dosage form Code submitted by the firm.
ROUTE NAMEINTRAOCULARThe translation of the route code submitted by the firm, indicating route of administration.
START MARKETING DATE2/1/2015This is the date that the labeler indicates was the start of its marketing of the drug product.
MARKETING CATEGORY NAMEOTC MONOGRAPH FINALProduct types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
APPLICATION NUMBERpart349This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
LABELER NAMEDIVISION 5 LABS, INC.Name of Company corresponding to the labeler code segment of the Product NDC.
SUBSTANCE NAMECARBOXYMETHYLCELLULOSE SODIUM, UNSPECIFIED FORMThis is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
ACTIVE NUMERATOR STRENGTH5 
ACTIVE INGRED UNITmg/mL 

Download Record

Download this NDC record in Text format: Export

Download this NDC record in Excel (CSV) format: Export

Download this NDC record in XML format: Export

This page was last updated on: 2/19/2021